Tetramethylpyrazine improves oxazolone-induced colitis by inhibiting the NF-κB pathway Abstract Purpose: Tetramethylpyrazine (TMP) is an e ective Chinese plant-derived medicine for colitis in the clinic, but the underlying molecular mechanisms of its use remain poorly understood. e purpose of this study was to investigate the mechanisms involved in its therapeutic action.
Ulcerative colitis (UC) and Crohn's disease (CD) are chronic human in ammatory bowel diseases (IBD), of which etiology and pathogenesis remain largely unknown. Previous studies showed that IBD is associated with genetic alterations [1] and environmental factors [2] [3] . It is characterized by the destruction of the gastrointestinal tract integrity, the excessive production of cytokines and the subsequent chronic intestinal inammation. Conventional therapies for IBD focus on suppression and control of in ammation by using 5-aminosalicylates, corticosteroids and immune-modulating drugs, but none of these has been found to be totally e ective [4] [5] [6] . While these drugs exhibit bene cial e ects on the treatment of IBD, they may impose risk to the patients. Development of new agents that combine pharmacologic e cacy and the absence of undesirable adverse e ects are critical. Tetramethylpyrazine (TMP), a puri ed and chemically identi ed component of Ligusticum wallichii or Ligusticum chuanxiong, used in Chinese traditional medicine, has been shown to prevent lipid peroxidation by scavenging oxygen free radicals. e use of TMP has been an innovative approach for the treatment of IBD. A previous study demonstrated that TMP can be used in UC treatment [7] , but the mechanism underlying its therapeutic action has still not been fully elucidated.
e intestinal epithelium has two important functions: it acts as a physical barrier separating luminal bacteria and immune cells and as an immunological barrier producing antimicrobial peptides and cytokines. Disruption of epithelial integrity by dysregulation of the NF-κB pathway causes spontaneous chronic in ammation because of translocation of bacteria into mucosa [8] . It has also been reported that the nuclear factor, NF-κB, plays an essential part in the regulation of a large number of genes involved in the immune and in ammatory responses [9] [10] ; therefore, the expression of NF-κB plays an important role in the pathogenesis of IBD. Under normal situations, the intestinal mucosa is in a state of 'controlled' inammation regulated by a delicate balance of proin ammatory (tumour necrosis factor (TNF-α), IL-1, IL-6 and IL-12) and anti-in ammatory cytokines (IL-4 and IL-10). e mucosal immune system is the central e ector of intestinal in ammation and injury, with cytokines playing a central role in modulating in ammation. Cytokines may, therefore, be a logical target for IBD therapy using speci c cytokine inhibitors. Agents targeted against TNFα, T-helper cell ( -1) activation or NF-κB, and other miscellaneous therapies, are being evaluated as potential therapies for IBD [11] . In iximab, a monoclonal antibody of TNFα, has emerged as an e cient treatment with many clinical bene ts such as quick disease activity reduction and IBD patient life quality improvement [12] . Reactive oxygen species (ROS) are also involved in the development of tissue injury in patients with IBD. Actually, the antiin ammatory e ects of corticosteroids, used in the treatment of IBD, have been partly ascribed to ameliorating oxidative insult [13] , and sulphasalazine has been suggested to produce bene cial e ects by inhibiting the formation of ROS from neutrophils [14] .
In this study, we investigated the activity of NF-κB in oxazolone-induced colitis in mice, which is an experimental colitis that has a histologic resemblance to human ulcerative colitis, and the e ect of tetramethylpyrazine on the activity of NF-κB. e results showed that TMP inhibited the NF-κB pathway, pro-in ammatory cytokine production and oxidative stress, which have important implications for the understanding and treatment of human ulcerative colitis.
Methods

Materials
Oxazolone was purchased from Sigma Chemical Company (St. Louis, MO, USA). Tetramethylpyrazine was produced by Wuxi Seventh Pharmaceutical Factory of China ( Jiangsu, China). NF-κB P65 and TBP antibodies were purchased from Abcam (Cambridge, UK). C-MYC, iNOS, COX-2 and β-actin antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Horseradish peroxidase-conjugated goat antirabbit antibody was purchased from Pierce (Rockford, IL, USA). TNF-α, IL-6, IL-8 and INF-γ ELISA Kit were purchased from R&D Systems (Minneapolis, MN, USA).
Animals
Seven-week-old male KM mice (25-30 g) were bred and maintained under speci c pathogen-free conditions in the Experimental Animal Center of Shanghai Jiao Tong University. Mice were housed under standard environmental conditions (21 o C, 60-70% humidity) with 12 h light/dark cycles and air ltration. All animal procedures were approved by the Animal Care Committees of Shanghai Jiao Tong University.
Induction of experimental colitis
e method of inducing colitis has been previously described by Heller et al. [15] . Forty-eight mice were randomized into six groups (n=8): non-colitic control group (N), oxazoloneinduced colitic group (Mod), saline-treated colitic group (NS), tetramethylpyrazine-treated group (80 mg/kg/day i.p.), SASPtreated group (100 mg/kg/day i.p.), TMP and SASP coadministered group. All mice were treated with oxazolone, ex-cept the normal control group. A piece of back skin with an area of 2cm×2cm was shaved in advance. Mice were sensitized by skin painting with 0.2 ml 3% oxazolone in 100% ethanol on two successive days. en ve days later the mice were challenged with the intrarectal administration of 0.15 ml 0.5% oxazolone in 50% ethanol. e disease activity index (DAI), which incorporates weight, stool consistency and hematochezia, was monitored daily (Supplementary Table 1 ). All mice were sacri ced on the fourth day a er enema. Representative whole gut specimens were taken from a region of the in amed colon corresponding to the segment adjacent to the gross macroscopic damage, and stained with hematoxylin and eosin. Stained sections were examined for evidence of colitis using a validated scoring system [16] .
Preparation of colonic epithelial cells and its lysate
Colonic epithelial cells were prepared as previously described [17] . e dissected colon was opened by cutting longitudinally and gently rinsed with ice-cold phosphate-bu ered saline (PBS). Fresh digestive enzymes were added for digestion, and the sample was shaken for 30 min at 37 o C. e cell suspension was collected by centrifugation, and this step was repeated ve times. e cells were then suspended in 33% Percoll and centrifuged for 20 min at 400 g. A er centrifugation, the cells on the top of the 33% Percoll were collected and used as epithelial cells. en, cytosol and nuclear proteins were separated by Nuclear and Cytoplasmic Extraction Reagents ( ermo Scienti c, Rockford, USA). e proteins were extracted according to the manufactures protocol.
Western blot
Proteins separated by gel electrophoresis were transferred to PVDF membrane (Millipore, Billerica, MA, USA). e membrane was blocked with Tris-bu ered saline (TBS-0.05% Tween 20) containing 3% bovine serum albumin. A er incubation with the appropriate primary antibody (NF-κB P65, COX-2, iNOS or C-MYC), bound antibody was detected by using peroxidase-conjugated secondary antibody and ECL Advance Western Blotting Detection Kit (GE Healthcare UK Ltd., Buckinghamshire, England).
Cell culture and treatment
e human colon adenocarcinoma cell line, Caco-2, was obtained from the American Type Culture Collection (ATCC). Cells were grown in DMEM supplemented with 10% FBS and 2 mM L-glutamine in a humidi ed 5% CO2 atmosphere at 37 o C. Caco-2 cells were seeded onto 6-well plates at a density of 2×10 5 cells per well and grown until formation of a monolayer. e cells were pretreated with TMP (40 µg/ml) for 24 h, and stimulated with lipopolysaccharide (LPS) for 6 h at a concentration of 100 ng/ml. e supernatants were collected, centrifuged at 10,000g for 5 min, and frozen until ELISA analysis of TNF-α, IL-6 and IL-8 concentration. Cytoplasm and nucleus proteins were then separated by Nuclear and Cytoplasmic Extraction Reagents for Western blot analysis of NF-κB P65 expression.
CD4 e ectors were generated as previously reported [18] . Puri ed naive CD4+ cells (3x10 5 /ml) were stimulated with IL-2 (10 µg/ml) and anti-IL-4 (10 µg/ml) for polarization to 1 e ectors in RPMI medium, supplemented with penicillin (200 µg/L), streptomycin (200 µg/L), and glutamine (4 µM) plus 10% selected FCS from Hyclone Labs (Logan, UT, USA). A er 5 d, 1 e ectors were harvested and seeded onto 6-well plates at a density of 2 x 10 5 cells per well. e cells were pretreated with TMP (40 µg/ml) for 24 h, and stimulated with lipopolysaccharide (LPS) for 6 h at a concentration of 100 ng/ ml. e supernatants were collected, centrifuged at 10,000g for 5 min, and frozen until ELISA analysis of INF-γ concentration. Cytoplasm and nucleus proteins were then separated by Nuclear and Cytoplasmic Extraction Reagents for Western blot analysis of INF-γ and P65 expression.
Measurement of ROS production
Caco-2 cells were loaded with 2 μM 2' ,7'-dichlorodihydrouorescein diacetate (H2DCF-DA) in serum-free low glucose-DMEM at 37 °C for 30 min and then washed twice with phosphate bu ered saline (PBS). H2DCF-DA uorescence was monitored with a ow cytometer (BD Bioscience, city, USA) at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. ROS was determined by comparing the changes in fluorescence intensity with that of the baseline (F/F0).
Statistical analysis
All results are expressed as the mean ± S.E.M., and the di erences between means were tested for statistical signi cance using one-way analysis of variance (ANOVA). Statistical signi cance was set at p < 0.05.
Results
TMP impro es oxazolone-induced colitis in mice
Mice were rapidly induced colitis by the administration of oxazolone marked by weight loss and diarrhea with or without hematochezia 24h a er challenge. Especially, this phenomenon was most severe on the third day in the model group. e disease activity index (DAI) score, a macroscopic score to assess colitis, showed that colitic model group was signi cantly higher than that of non-colitic group over 4 days (s 1). TMP, as well as SASP, signi cantly improved the status of mice colitis and the co-administration of TMP and SASP had a synergistic e ect on disease.
On histological examination, the histological features of the colon from normal group mice were typical of a normal structure ( Figure 1A ). Oxazolone-induced colitis model group showed in amed colon walls with brotic thickening of tissue, extensive ulceration and in ammation involving all the intestinal layers of the colon ( Figure 1B) . ese samples were also characterized by severe edema and interstitial microhemorrhages. e macroscopic analysis of the colonic specimens in the colitic rats revealed existence of severe necrosis and in ammation of the mucosa.
TMP showed an anti-in ammatory e ect in colitis mice, similar to the e ects obtained with SASP, as demonstrated by the decreased ulcers of colonic mucosa ( Figure 1D , E), but not in saline group ( Figure 1C) . us, the histological studies showed that treatment with TMP or SASP promoted recovery of the intestinal cytoarchitecture, the reduction of ulceration and edema, and depletion of mucus in the submucosal layers. In addition, co-administration of TMP and SASP produced a much stronger protective e ect ( Figure 1F ). Brie y, the histological scores in colitis groups was signi cantly higher than that in normal control group, and TMP signi cantly improved the histological features, as well as SASP. And the coadministration of TMP and SASP had a synergistic e ect (Table 1).
TMP inhibits activation of NF-κB in colonic epithelial cells
To investigate the molecular mechanisms, epithelial cells were isolated from the colon samples. e cytoplasm and nucleus proteins were extracted separately. In the colitis model group, NF-κB P65 was translocated to the nucleus as shown by a decrease in cytoplasmic and an increase in nuclear protein levels, indicating the activation of NF-κB. As shown in Figure 2 . TMP alleviated the oxazolone-induced colitis. Mouse colitis was induced by the administration of oxazolone, representative specimens were taken from a region of colon, and full-thickness sections of 6 µm of colon mucosa were obtained and stained with hematoxylin and eosin for histological examination. Oxazoloneinduced colitis model group showed colon wall was in amed with brotic thickening of tissue. e colitis model also exhibited extensive ulceration. TMP showed an anti-in ammatory e ect on colitis, similar to the e ects of SASP, as demonstrated by a decrease in ulcers of colonic mucosa. A) non-colitic group, B) oxazolone-induced colitic group, C) saline-treated colitic group, D) tetramethylpyrazine treated group, E) SASP treated group, and F) TMP and SASP coadministrated group. e magni cation is 40×. strated by the decreased cytoplasmic p-IKBα and increased cytoplasmic NF-κB p65 protein levels, which lead to the decreased nuclear NF-κB p65 protein levels. Similar results were observed in SASP treatment group. In addition, the coadministration of TMP with SASP showed a synergistic e ect in repression of nucleus transportation of NF-κB P65.
TMP inhibits the expression of NF-κB downstream pathway
As is well known, the nucleus translocation of NF-κB induces the transcription of a number of in ammation and cell proliferation-related genes. Among them, iNOS, COX-2 and C-MYC are well-known downstream proteins associated with the activation of NF-κB. us, the expression of these proteins was assessed by Western blot analyses. As shown in Figure 3 , the expression of C-MYC, iNOS and COX-2 were signicantly elevated in colitis model group, as compared with the control group. e saline treatment group did not show any signi cant change in the expression of these proteins, while the TMP group as well as the SASP group demonstrated a dramatic decrease in the expression of C-MYC, iNOS and COX-2. Much more reduction in the expression is observed in the co-administration group.
TMP inhibits the activation of NF-κB in cultured Caco-2 cell lines
Caco-2 cells were pretreated with TMP (40 µg/ml) for 24 h and then exposed to LPS (100 ng/ml) for 6 h. LPS promoted the NF-κB translocation into nucleus of Caco-2 cells as indicated by redistribution of protein level of NF-κB P65, which was decreased in cytoplasm and increased in nucleus, compared with the vehicle-treated group ( Figure 4A ported by the observation that 24 h of TMP pretreatment upregulated cytoplasmic NF-κB P65 protein levels and decreased nuclear NF-kB P65 protein levels.
Inhibition of in ammatory factors and ROS production in cultured cells
Further measurements were performed to investigate whether TMP could exert an inhibition on NF-κB downstream proinammatory factors in colonic cells a er stimulation with LPS. e cells were pretreated with TMP (40 µg/ml) for 24 h and then treated with LPS (100 ng/ml) for 6 h. e results obtained in these assays showed that TMP signi cantly reduced the production of di erent cytokines induced by LPS ( Figure  4B ). In LPS-stimulated Caco-2 cells, the production of TNF-α, IL-6 and IL-8 was signi cantly increased by LPS, while TMP signi cantly reduced the secretion of TNF-α, IL-6 and IL-8 into culture medium induced by LPS.
T helper cell 1 ( 1) is the host immunity e ector against intracellular bacteria and protozoa. 1 are triggered by IL-12, IL-2 and their e ector cytokine, IFN-γ. 1 also plays an important role in colitis.. As shown in Figure 4C similar results. TMP also inhibited the nuclear translocation of NF-κB P65, as demonstrated by the increase of P65 in cytoplasm and decrease of P65 in the nucleus, which inhibited the activation of P65 by LPS. e ROS production can be induced by the activation of NF-κB, which is also involved in the development of colitis. Accordingly, the possibility that TMP modulates LPS-induced intracellular ROS formation in Caco-2 cells was examined. e results showed that TMP pretreatment signi cantly inhibited LPS-induced intracellular ROS formation in Caco-2 cells ( Figure 4D ).
Discussion
Recently, substantial advances in the understanding of the molecular pathogenesis of in ammatory bowel disease (IBD) have been made [19] . First, IBD has been found to be the most tractable of complex disorders for discovering susceptibility genes, which are related to epithelial barrier function, and innate and adaptive immunity. Second, e orts directed towards the identi cation of environmental factors implicate commensal bacteria (or their products) as drivers of IBD. ird, murine models, which exhibit many of the features of ulcerative colitis, have helped unravel the pathogenesis/mucosal immunopathology of IBD.
us, IBD is a complex disease that includes the microbial-innate-immune-response interaction during the transition from physiological to pathological intestinal inammation. Currently, the therapeutic e ciency is still limited due to the complexity of IBD; thus, nding an e cient way to treatment of IBD is still urgently needed.
In traditional oriental medicine, Ligusticum wallichii Franchat (Ligusticum chuanxiong) is widely used for the treatments of many ischemia disorders such as neurovascular and cardiovascular diseases. Tetramethylpyrazine (TMP), a puri ed and chemically identi ed component of chuanxiong, can prevent lipid peroxidation by scavenging highly reactive free radicals. It has been shown that TMP can alleviate kidney and brain damage by scavenging free radicals [20] [21] . TMP had been used for the treatment of ulcerative colitis in China; however, its molecular mechanism has not been fully explored. In this study, TMP was found to reduce the colitis induced by oxazolone in a modi ed oxazolone-induced colitis mouse model, and the combination of TMP with SASP had a synergistic e ect, suggesting that these two compounds could be used together for the treatment of colitis.
As NF-κB has dual e ect on colitis: NF-kB is important to resolve in ammation in a controlled state, which as a barrier separating luminal bacteria and immune cells, and as an immunological barrier producing antimicrobial peptides and cytokines. NF-κB is also a pivotal protein involved in proin ammatory signal transduction. e activation of NF-κB has been demonstrated in colonic epithelial cells and macrophages of patients with IBD [22] [23] . Numerous and diverse stimuli can induce NF-κB activity. Typical inducers of NFκB include cytokines, such as tumour necrosis factor (TNF), interleukin1 (IL1) and viral and bacterial products, such as lipopolysaccharide (LPS) and cellular stress. NF-κB p65 antisense oligonucleotide treatment was reported to be bene cial to experimental colitis [24] .
To explore the molecular mechanisms, the e ect of TMP on NF-κB activity was investigated. TMP was found to inhibit the nucleus translocation of NF-κB, and suppress its downstream pathways, such as iNOS, COX-2 and C-MYC, which play a critical role in the in ammation and cell proliferation.
e co-administration of TMP and SASP dramatically inhibited NF-κB pathway. ese results indicated that the inhibition on NF-κB pathway is critical for the pharmacological e ect of TMP.
Further, the colonic cell line, Caco-2, was used as a cellular model by pretreating with TMP and then exposing the cells to LPS. e results showed that TMP signi cantly inhibited the nucleus translocation of NF-κB induced by LPS, and its downstream proin ammatory factors, such as TNF-α, IL-6 and IL-8 were also decreased. ROS plays an important role in the pathogenesis of colitis, which is also decreased by TMP, demonstrated the anti-oxidative stress e ect of TMP. As T helper cell 1 is involved in colitis, thus the e ect of TMP on 1 was also investigated at cellular level. e result showed TMP could inhibit the 1 activation, as re ected by decreased INF-γ production and NF-κB activation.
ese results suggested TMP has an anti-in ammatory e ect in colitis that is induced by LPS.
In conclusion, this study showed TMP could alleviate the colitis induced by oxazolone, which is related to the inhibition of NF-κB pathway, and suppress downstream signaling, via iNOS, COX-2, C-MYC and cytokine production, as well as decrease ROS production.
e combination of TMP and SASP has a synergistic e ect in animal models, suggesting that the combination may be bene cial for clinical treatment.
